药物在减少接受某些化疗的癌症患者的心脏损伤方面显示出希望。 Drug shows promise in reducing heart damage in cancer patients undergoing certain chemotherapy.

一种心脏衰竭的药物,sabibitril-valsartan, 已经显示出在减少癌症患者心脏损伤方面的潜力。 A heart failure drug, sacubitril-valsartan, has shown potential in reducing heart damage in cancer patients receiving anthracycline chemotherapy. 在对114名高危病人进行的一项研究中,与安慰剂相比,该药物与进一步心脏病损伤风险降低77%有关。 In a study of 114 high-risk patients, the drug was linked to a 77% lower risk of further heart damage compared to a placebo. 药物改善了心脏功能,但还需要对不同的病人群体进行更多的研究,以证实研究结果。 The medication improved heart function, but more research is needed on diverse patient groups to confirm the findings.